<DOC>
	<DOCNO>NCT01193296</DOCNO>
	<brief_summary>The study assess glycemic variability optimize glycemic control T2DM patient treat DPP-4 inhibitor add-on therapy metformin .</brief_summary>
	<brief_title>Glycemic Holter Study ( Continuous Glucose Monitoring ) -</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Type 2 Diabetes Mellitus ( DM ) willing perform SMBG least 6 time daily use MiniMed CGMS 3 consecutive day 2 occasion . HbA1c : 6.5 9 % metformin monotherapy least 3 month Age &gt; = 80 year BMI &lt; = 22 &gt; =40 kg/m2 Secondary T2 DM Hepatic failure , ASAT/ALAT &gt; 3 ULN , moderate/severe renal failure ( CI &lt; 50 ml/min ) CHF III &amp; IV Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Diabetes mellitus , vildagliptin , continuous glucose monitoring</keyword>
</DOC>